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Abstract: Immunoglobulin E (IgE) is central to the pathophysiology of allergic asthma. 
Omalizumab, an anti-IgE monoclonal antibody, binds to the FcεRI binding site on free IgE. 
As a result, circulating free IgE is reduced, IgE is prevented from attaching to mast cells and 
basophils, and FcεRI receptor expression is down-regulated. The inflammatory response 
to allergens and the acute and chronic effector phases of allergic inflammation are thereby 
attenuated. In clinical trials in adults and adolescents, omalizumab reduced asthma exacerba-
tions, severe asthma exacerbations, inhaled corticosteroid requirements, and emergency visits, 
as well as significantly improving asthma-related quality of life, morning peak expiratory flow 
and asthma symptom scores in patients with severe allergic (IgE-mediated) asthma. Results 
from clinical trials in children (12 years) are consistent with those in the adult population. 
It is difficult to predict which patients will respond to omalizumab. Responders to omalizumab 
should be identified after a 16-week trial of therapy using the physician’s overall assessment. 
When treatment is targeted to these responders, omalizumab provides a cost-effective therapy 
for inadequately controlled severe allergic (IgE-mediated) asthma. Long-term therapy with 
omalizumab shows the potential for disease-modification in asthma. Ongoing studies are also 
evaluating the use of omalizumab in other non-asthma IgE-mediated conditions.
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Introduction
Atopy, a genetic predisposition to the production of immunoglobulin E (IgE), is the 
underlying cause of most cases of asthma.1–3 In atopic asthma, sensitization to an 
allergen results from activation of Th2- and B-lymphocytes, leading to release of 
cytokines such as IL-4 and IL-13 and production of IgE antibodies.4 IgE antibodies 
bind to high-affinity (FcεRI) receptors on mast cells and basophils. Subsequent 
allergen exposure results in the formation of cross-links between cell-bound IgE, 
leading to cell degranulation and release of pro-inflammatory mediators such as his-
tamine, tryptase, leukotrienes and prostaglandins.5 These mediators are responsible 
for early-phase allergic reactions and promote late-phase reactions by stimulating 
release of IL-4 from mast cells, leading to positive feedback to Th2 lymphocytes 
and sustained secretion of cytokines. Mast cells also release mediators that promote 
up-regulation of adhesion molecules in endothelial cells, resulting in accumulation 
of eosinophils, basophils and lymphocytes, ultimately leading to airway hyperre-
sponsiveness.5–7
The pathophysiology of asthma shares a number of similarities with other allergic 
conditions, especially allergic rhinitis,8 in which IgE also plays a central role in the Journal of Asthma and Allergy 2009:2 50
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underlying inflammation. This link between atopy and 
asthma/rhinitis provides a strong rationale for developing 
treatments that target IgE.
A previous review provided an overview of the develop-
ment, mechanism of action and clinical efficacy and safety 
of the monoclonal anti-IgE antibody, omalizumab.9 Since 
its publication, additional studies have been completed and 
further clinical experience has been gained with the use of 
omalizumab. The present article therefore provides an update 
on the treatment of allergic (IgE-mediated) asthma through 
targeting of IgE with omalizumab, and provide an overview of 
the current understanding of the anti-inflammatory effects of 
omalizumab and its potential role in IgE-mediated diseases.
Development of omalizumab
Omalizumab was originally identified using somatic cell 
hybridization techniques.10 A murine monoclonal anti-human 
IgE antibody (MaE11) was found to have activity directed at 
the FcεRI binding site on the human IgE molecule.11,12 By 
grafting the complementarity-determining region of MaE11 on 
to a human immunoglobulin G (IgG) framework,13 a human-
ized omalizumab molecule containing only 5% murine resi-
dues was produced. As omalizumab binds to the same binding 
site as FcεRI, it can neither bind to IgE that is already bound 
to the surface of a cell12,13 nor form cross-links between IgE 
molecules on the cell surface.14 This inability to cross-link cell-
bound IgE, combined with the small amount of murine residue, 
results in a low risk of anaphylaxis with omalizumab.
IgE, FcεRI and the allergic response
Administration of omalizumab at a dose approximately equal 
to 0.016 mg/kg IgE (IU/mL) per 4 weeks reduces serum 
free IgE by between 89% and 99% in patients with allergic 
asthma,15,16 and similar reductions have been observed in 
patients with allergic rhinitis.17–20 This reduction in free IgE 
is accompanied by a reduction in the expression of FcεRI on 
the cell surface. In one study (n = 15), omalizumab treatment 
resulted in a 99% decrease in free IgE, and a 96% reduction in 
the median density of FcεRI on basophils following 3 months 
of therapy.21 Similarly, a 6-week study in patients with aller-
gic rhinitis (n = 24) revealed a 73% reduction in basophil 
FcεRI expression within 14 days of treatment.20 Omalizumab 
has also been shown to reduce FcεRI expression on skin mast 
cells in patients with allergic rhinitis22 and bronchial mast 
cells in patients with asthma.23 Furthermore, omalizumab 
down-regulated FcεRI expression on precursor dendritic cells 
over 6 weeks in patients with ragweed-sensitive seasonal 
allergic rhinitis (SAR; n = 24),20 with similar effects reported 
in patients with atopic dermatitis over 16 weeks (n = 20).24 
This down-regulation of receptors on dendritic cells might 
inhibit antigen processing and presentation to T cells, and 
could potentially result in blockade of the sensitization phase 
of the allergic response, as well as the effector phase.
By reducing free IgE and down-regulating FcεRI expres-
sion on mast cells and basophils, omalizumab attenuates both 
the early and late allergic responses. In a study of 19 patients 
with stable, mild, allergic asthma, omalizumab was shown 
to attenuate reductions in forced expiratory volume in one 
second (FEV1) during both the early (0–1 hour) and late 
(2–7 hours) phases after allergen challenge.25 Attenuation 
of early responses was also evident in a study in patients 
with stable, mild, allergic asthma (n = 20), which showed 
that treatment with omalizumab significantly (p  0.002) 
increased the provocation concentration of allergen causing 
a 15% decline in FEV1 (PC15).26 More recently, a study in 
24 patients with mild allergic asthma showed that omali-
zumab reduced the maximal percentage fall in FEV1 during 
both the early (0–3 hours after allergen challenge) and late 
(3–7 hours) phases after allergen challenge.27
The effect of omalizumab on airway hyperresponsiveness 
to methacholine in patients with mild allergic asthma.25,26 
Significant reductions were reported in one study;26 however, 
in a larger study of patients with mild-to-moderate persistent 
asthma and sputum eosinophilia, hyperresponsiveness to 
methacholine did not improve following 16 weeks of omali-
zumab therapy.23 The effect of omalizumab on eosinophils is 
established (see ‘Anti-inflammatory activity’ below), leading 
the authors of the study to conclude that IgE and eosinophils 
may not be causally linked to methacholine hyperresponsive-
ness in mild-to-moderate persistent asthma.23
Summary of clinical data
Omalizumab is indicated in the USA as add-on therapy 
for adults and adolescents (12 years of age and older) with 
moderate-to-severe persistent asthma who have a positive 
skin test or in vitro reactivity to a perennial aeroallergen and 
whose symptoms are inadequately controlled with inhaled 
corticosteroids (ICS).28 In Europe, the indication differs in 
that patients (12 years of age and above) should have severe 
persistent allergic asthma, a positive skin test or in vitro 
reactivity to a perennial aeroallergen, reduced lung function 
(FEV1  80%), frequent daytime symptoms or night-time 
awakenings, and multiple documented severe asthma exac-
erbations despite daily high-dose ICS plus a long-acting 
β2-agonist (LABA).29 The data supporting these indications 
have been reviewed previously9 and are summarized below Journal of Asthma and Allergy 2009:2 51
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along with a more detailed evaluation of newly published 
studies. In addition, in light of the need for new add-on thera-
pies for children with inadequately controlled asthma, studies 
conducted in a pediatric setting are also reviewed.
Moderate-to-severe asthma
Efficacy of omalizumab
Omalizumab has been evaluated as an add-on therapy 
in seven large-scale trials in adults and adolescents with 
moderate-to-severe allergic asthma. Five of these studies 
were described in detail in the previous review and are sum-
marized in Table 1.15,16,30–32
In all seven studies, omalizumab was administered as 
add-on therapy every 2 or 4 weeks to provide a dose of at 
least 0.016 mg/kg per IU/mL of IgE according to patients 
bodyweight and baseline IgE levels using a dosing table.33 All 
studies evaluated the effect of omalizumab on asthma exacer-
bations, among other endpoints. The definition of an asthma 
exacerbation varied between studies – asthma exacerbation 
was defined as: worsening of asthma requiring treatment with 
systemic corticosteroids in three studies,30,31,34 worsening of 
asthma requiring treatment with systemic corticosteroids 
or a doubling of the baseline inhaled corticosteroid dose in 
three studies15,16,32 and, in the seventh study, worsening of 
asthma requiring unscheduled medical care, an emergency 
room visit or hospitalization and one or more of doubling 
of ICS dose, increase in dose of oral corticosteroids (OCS) 
or initiation of systemic corticosteroids.35 As noted in the 
previous review, the clinical trials of omalizumab showed 
that treatment reduced the rate of asthma exacerbations 
(Table 1) and led to reductions in inhaled corticosteroid 
requirements.9 Since the publication of that review, data have 
become available from another randomized, controlled trial, 
the INNOVATE study.34
The INNOVATE study enrolled 419 patients with severe 
persistent asthma that was inadequately controlled despite step 
4 treatment as described in the Global Initiative for Asthma 
(GINA) 2002 guidelines.34,36 After correction for an imbalance 
in the history of clinically significant asthma exacerbations 
(defined as worsening of asthma requiring treatment with 
systemic corticosteroids), the clinically significant asthma 
exacerbation rate (the primary endpoint) was significantly (p 
= 0.042) lower at week 28 in patients receiving omalizumab 
(0.68) than in the placebo group (0.91; Figure 1). Prior to this 
correction, there was a similar, but statistically non-significant, 
between-group difference in asthma exacerbations (rate ratio 
0.806; p = 0.153). Without correction for baseline imbalance, 
omalizumab also resulted in significantly lower rates of 
severe asthma exacerbations (defined as an exacerbation 
in which peak expiratory flow (PEF) or FEV1 was 60% 
of personal best, and requiring treatment with systemic 
corticosteroids; 0.24 vs 0.48, p = 0.002) and emergency visits 
Table 1 Studies of omalizumab in adults and adolescents with moderate-to-severe allergic asthma35
Study  Patients  Study  
treatments
Study duration  
(weeks)
Annual exacerbation rate 
n Characteristics Between-group 
difference
Reduction (%) P-value
Busse study15 525 Severe allergic asthma  
requiring daily iCS
Omal + iCS vs  
placebo + iCS
52 0.40 40.3% 0.001
Solèr study16 546 Moderate-to-severe allergic  
asthma, symptomatic despite iCS
Omal + iCS vs  
placebo + iCS
52 0.70 57.6% 0.001
Holgate study31 341 Severe allergic asthma Omal + iCS vs  
placebo + iCS
32 0.42 26.5% 0.165
iNNOvATe study34 419 Poorly controlled severe  
persistent allergic asthma
Omal + iCS vs  
placebo + iCS
28 0.49 26.6% 0.039
eTOPA study30 312 Poorly controlled, moderate- 
to-severe allergic asthma
Omal + CAT vs  
placebo + CAT
52 1.49 60.4% 0.001
SOLAr study32 405 Moderate-to-severe asthma  
and persistent allergic rhinitis
Omal + iCS vs  
placebo + iCS
28 0.29 37.5% 0.027
ALTO safety studya 1899 Severe asthma Omal + CAT vs  
placebo + CAT
24 0.18 15.3% 0.077
Pooled analysis35 4308 Severe (93% of patients) or  
moderate asthma
Omal vs control Annualized 0.56 29.3% 0.0001
aUnpublished study (data on file at Novartis).
Abbreviations: Omal, omalizumab; iCS, inhaled corticosteroids; CAT, current asthma therapy.Journal of Asthma and Allergy 2009:2 52
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(0.24 vs 0.43, p = 0.038) as well as significant improvements 
in asthma-related quality of life (p  0.001), morning 
PEF (p = 0.042) and asthma symptom scores (p = 0.039).
The INNOVATE trial was included in a pooled analysis, 
along with the six other studies.35 The pooled population 
consisted of 4308 patients, 93% of whom had severe persis-
tent asthma according to the GINA 2002 classification. In 
omalizumab recipients, the rate of asthma exacerbations was 
reduced by 38% (p  0.0001) and the rate of total emergency 
visits by 47% (p  0.0001) compared with the control groups. 
Subgroup analyses showed that age, gender, baseline serum IgE 
and dosing schedule did not affect the efficacy of omalizumab 
on asthma exacerbation rates (Figure 2). However, treatment 
benefits appeared to be numerically greater in patients with 
lower percentage predicted FEV1 values.
Reflecting the European label population, an analysis of 
the severe subpopulation from a 1-year open-label study30 in 
patients with moderate-to-severe allergic asthma has recently 
been published.37 The analysis found that, in the severe sub-
population, adding omalizumab to best standard care (BSC) 
significantly improved efficacy outcomes compared with 
BSC alone. The analysis included 164 patients (omalizumab 
n = 115; control, n = 49) receiving high-dose ICS plus a 
LABA. At 1 year, the annual asthma exacerbation rate was 
reduced by 59% in omalizumab-treated patients, compared 
with the control group (1.26 vs 3.06; p  0.001), and there 
were also significant improvements in percentage predicted 
FEV1 (p  0.05), asthma symptoms (p  0.05) and mini-
Asthma Quality of Life Questionnaire scores (p  0.001).
Data from the seven studies included in the pooled analysis 
have been analysed to determine whether pre-treatment 
characteristics could be used to predict outcomes, and to 
evaluate methods of identifying treatment responders.38 
Analysis of INNOVATE study data showed that baseline total 
IgE was the only predictor of efficacy; however, pooled data 
analysis showed that treatment was beneficial regardless of 
IgE levels. Overall, the analyses showed that it is not possible 
reliably to predict the outcomes of omalizumab treatment based 
on pre-treatment characteristics. To identify responders, the 
physician’s overall assessment after 16 weeks of omalizumab 
therapy provided the best discrimination of treatment outcomes. 
The physician’s overall assessment comprises multiple aspects 
of response, including patient interview, review of medical 
notes, spirometry, symptom diaries, rescue medication use 
and PEF. In omalizumab clinical trials, a physician’s overall 
assessment was graded in a five level evaluation (complete 
control; marked improvement in control; discernible but limited 
control; no appreciable change; worsening in control). Patients 
achieving complete or marked improvement in control were 
classified as responders. Based on the findings from these 
analyses, it is recommended that targeting omalizumab to 
patients most likely to benefit can best be achieved by using 
the physician’s overall assessment to identify responders at 
16 weeks, rather than by selecting patients according to baseline 
characteristics.38 The ongoing EXHALT study will examine 
the persistency of treatment response to 32 weeks in patients 
classified as responders after 16 weeks.39
Pediatric asthma
Atopic diseases such as asthma, rhinitis and atopic dermatitis 
are increasingly prevalent among children.40 The International 
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Figure 1 Clinically significant asthma exacerbations in the INNOVATE study. 
Reproduced with permission from Humbert M, Beasley R, Ayres J, et al. Benefits of 
omalizumab as add-on therapy in patients with severe persistent asthma who are 
inadequately controlled despite best available therapy (GiNA 2002 step 4 treatment): 
iNNOvATe. Allergy. 2005;60:309–316. Copyright © 2005 Blackwell Publishing.
aAdjusted due to a pre-study imbalance in exacerbation rate.
Age: 12 to <18 years
18 to <65 years
≥65 years
Male
Female
Predicted FEV1: <60%
60 to <80%
≥80%
Serum total IgE: < Median 
≥ Median
Dosing schedule: 4-weekly 
2-weekly
(n = 298)  
(n = 3734) 
(n = 241) 
(n = 1740)  
(n = 1136)
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(n = 2533) 
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Rate ratio (logarithmic scale)
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Figure 2 relative rates of asthma exacerbations across subgroups in pooled studies 
of omalizumab in patients with moderate-to-severe asthma: point estimates and 95% 
confidence intervals for asthma exacerbation rate ratios (omalizumab: control) from 
Poisson regression models. reproduced, with permission, from Bousquet J, Cabrera P, 
Berkman N, et al. The effect of treatment with omalizumab, an anti-ige antibody, on 
asthma exacerbations and emergency medical visits in patients with severe persistent 
asthma. Allergy. 2005;60:302–308.35 Copyright © 2005 Blackwell Publishing.
Abbreviations: Fev1, forced expiratory volume in 1 second; ige, immunoglobin e.Journal of Asthma and Allergy 2009:2 53
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Study of Asthma and Allergies in Childhood (ISAAC) surveys 
indicated that severe asthma affects 2.0% to 8.3% of 13- to 
14-year-old children and 1.4% to 6.9% of 6- to 7-year-olds in 
Western Europe, with similar prevalences in the USA (6.1% 
of 13- to 14-year-olds).41 Control of asthma in children is also 
far from optimal. The Asthma Insights and Reality in Europe 
(AIRE) study showed that only 5.8% of children with asthma 
met all of the GINA 2002 criteria for asthma control.42 While 
lack of asthma control may often be due to inadequate treat-
ment, there is also evidence that many children have poorly 
controlled asthma despite intensive treatment. For example, 
a US survey showed that 53% of children (6–11 years) and 
44% of adolescents (12–17 years) required an OCS burst and 
25% and 19%, respectively, had an emergency room visit in 
the previous 3 months, despite using three or more long-term 
controller medications.43 There is clearly a need to improve 
asthma control in many children with severe asthma.
Efficacy of omalizumab
Although omalizumab is not currently indicated in 
patients 12 years, the efficacy and safety of omalizumab 
has been evaluated in two double-blind, randomized, placebo-
controlled studies. The first enrolled 334 children (aged 
6–12 years) with moderate-to-severe allergic (IgE-mediated) 
asthma that was well controlled with ICS.44 Children com-
pleted a run-in phase during which they were switched to 
equivalent doses of beclomethasone and the dose adjusted 
to maintain asthma control, before randomization to add-on 
omalizumab or placebo. Beclomethasone doses were kept 
constant during a 16-week stable-steroid phase, reduced 
during an 8-week steroid-reduction phase, and then kept 
constant for the remaining 4 weeks of the study. At the end 
of the study, children in the omalizumab group had achieved 
significantly greater median reductions in beclomethasone 
dose than those receiving placebo (primary endpoint; 100% 
vs 66.7%, p = 0.001; Figure 3). In the omalizumab group, 
55% of children were able to discontinue ICS, compared with 
39% of the placebo group (p = 0.004). Despite the reduc-
tions in ICS doses, children receiving omalizumab had fewer 
asthma exacerbations requiring treatment with doubling of 
beclomethasone dose or systemic corticosteroids, compared 
with placebo. Additionally, investigators were more likely to 
rate the effectiveness of omalizumab as excellent (31.5%) or 
good (44.7%), compared with placebo (16.3% and 32.7%, 
respectively), with similar results for the patients’ ratings of 
treatment effectiveness. Quality of life, assessed using the 
Paediatric Asthma Quality of Life Questionnaire (PAQLQ), 
showed significant (p  0.05) improvements in the activities 
and symptoms domain scores as well as in overall quality of 
life at the end of the steroid-reduction phase in the omalizumab 
group, compared with placebo.45 Omalizumab recipients 
were also more likely to have clinically relevant changes in 
PAQLQ scores (0.5 point improvement) during the study, 
with significant (p  0.05) differences for activities and overall 
quality of life.
More recently, a 52-week study evaluated the efficacy 
and safety of omalizumab in 628 children with inadequately 
controlled, moderate-to-severe persistent allergic (IgE-
mediated) asthma.46 Children received an optimized asthma 
care programme and were randomized (2:1) to either omali-
zumab or placebo during a 24-week fixed steroid phase and 
28-week adjustable steroid phase. Efficacy was evaluated 
in 576 children (omalizumab, n = 384; placebo, n = 192), 
the primary efficacy variable being the rate of clinically 
significant asthma exacerbations during the fixed-steroid 
period. The rate of clinically significant asthma exacerba-
tions during the 28-week steroid-adjustable phase was also 
assessed. After the 24-week fixed-dose steroid treatment 
period, children treated with omalizumab showed a 31% 
decrease in the rate of clinically significant asthma exacer-
bations compared with placebo (0.45 vs 0.64, p = 0.007). 
During the following 28 weeks, children treated with omali-
zumab showed a 54.2% decrease in the clinically significant 
asthma exacerbation rate compared with placebo (0.32 vs 
0.71, p  0.001). Of note, in the sub-group of children who 
were receiving high-dose ICS and LABA (corresponding to 
the current EU indication in adults), children treated with 
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Figure 3 Percentage of patients with reduction in dose of inhaled steroid at end of 
treatment in a study of omalizumab in a paediatric setting. reproduced with permission 
from Milgrom H, Berger w, Nayak A, et al. Treatment of childhood asthma with 
anti-immunoglobulin e antibody (omalizumab). Pediatrics. 2001;108:e36.44 Copyright © 
2001 by the AAP.Journal of Asthma and Allergy 2009:2 54
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omalizumab showed a 34% decrease (p = 0.047) in the rate 
of clinically significant asthma exacerbations compared with 
placebo during fixed steroid phase, and a 63% decrease 
(p  0.001) during the adjustable steroid phase.
Allergic rhinitis
Allergic asthma and allergic rhinitis frequently co-exist, 
and are often considered to be components of a single 
IgE-mediated inflammatory condition.47,48 Several trials of 
omalizumab have been conducted in patients with allergic 
rhinitis, and have been reviewed previously.9 In brief, they 
included two studies in patients with SAR17,18 and one 
in patients with perennial allergic rhinitis (PAR).49 In all 
three studies, omalizumab significantly reduced symptom 
severity and rescue antihistamine use, as well as significantly 
improving rhinitis- or rhinoconjunctivitis-related quality of 
life in SAR (quality of life was not assessed in PAR). The 
previous review also summarized the results of the SOLAR 
study, which evaluated omalizumab in patients with con-
comitant asthma and PAR,32 and showed that in addition to 
reducing asthma exacerbations (Table 1), omalizumab also 
improved asthma and rhinitis scores on quality of life scales 
and led to significant (p  0.001) improvements in rhinitis 
symptoms.
A recent post hoc analysis of data from SOLAR showed 
that the omalizumab-treated patients who achieved the 
greatest benefits in terms of their asthma symptoms also 
had the best outcomes for their rhinitis symptoms.50 In 
this analysis, patients were classified as asthma responders 
based on the physician’s overall assessment, while rhinitis 
responders were identified using the Rhinitis Quality of 
Life Questionnaire (RQLQ) questionnaire. Among the 
123 (59.4%) omalizumab-treated patients who were identified 
as asthma responders, there was a significantly (p  0.001) 
greater likelihood of a rhinitis response, compared with 
placebo. Omalizumab-treated asthma responders were 
also more than 3 times as likely to have a rhinitis response 
than omalizumab-treated patients who were not classified 
as asthma responders (odds ratio 3.56; 95% CI 1.94–6.54; 
p  0.05). As well as providing further evidence of the 
etiological link between rhinitis and asthma, these results 
suggest that omalizumab may provide additional benefit to 
omalizumab-treated asthma patients who also suffer with 
allergic rhinitis.
immunotherapy
Allergen-specific immunotherapy (SIT) involves a gradual 
administration of increasing quantities of a standardized 
allergen extract to an allergic subject over time in order 
to alleviate the allergic response of that subject to the caus-
ative allergen.51 The recognition of IgE as a key mediator in 
allergic disease and the interruption of the allergic cascade 
with omalizumab have led to the hypothesis that administra-
tion of omalizumab with SIT may increase the safety and 
efficacy of SIT. Accordingly, several studies have evaluated 
omalizumab in conjunction with SIT. Casale et al investi-
gated the addition of omalizumab to rush immunotherapy 
(RIT) in adults with ragweed allergic rhinitis.52 Patients 
(n = 159) received 9 weeks of omalizumab or placebo, 
followed by 1-day of RIT or placebo immunotherapy and 
a further 12 weeks of omalizumab or placebo plus immu-
notherapy. By the end of treatment, ragweed-specific IgG 
levels had increased by more than 11-fold in immunotherapy 
patients, while free IgE levels decreased by more than 10-fold 
in omalizumab recipients. Additionally, the incidence of 
adverse events (AEs) was lower in patients receiving omali-
zumab plus RIT than in those receiving RIT alone, and there 
was a 5-fold decrease in the risk of anaphylaxis due to RIT. 
Symptom severity scores were also significantly improved 
during the ragweed season in patients receiving omalizumab 
plus RIT, compared with RIT alone (0.69 vs 0.86; p = 0.044). 
Overall, these findings indicated that omalizumab could 
improve the safety of RIT for allergic rhinitis and may 
permit the use of more rapid and higher doses of allergen 
immunotherapy.
The combination of SIT and omalizumab was also 
more effective than either treatment alone in a study of 
221 children and adolescents with SAR.53 Patients received 
SIT or placebo along with omalizumab or placebo before 
and during pollen seasons for a total of 24 weeks. The 
combination of SIT and omalizumab reduced symptom load 
by 48% compared with SIT alone. Similar findings were 
reported from a study in 221 children and adolescents with 
allergic rhinoconjunctivitis.54 Treatment with SIT before 
the pollen season did not improve symptoms or rescue 
medication use when used alone, but the concomitant use 
of omalizumab and SIT resulted in significant (p  0.001) 
reductions in rescue medication use and the number of 
symptomatic days. More recently, results from a random-
ized, double-blind, placebo-controlled trial showed that 
omalizumab in combination with depigmented SIT reduced 
symptom load by 39% (p = 0.0464), compared with depig-
mented SIT alone, during the pollen season in patients 
with co-morbid seasonal allergic asthma and SAR.55 This 
combination also improved asthma control and asthma-
related quality of life.Journal of Asthma and Allergy 2009:2 55
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Other allergic conditions
Targeting IgE is a rational approach in the treatment of 
other IgE-mediated conditions other than asthma or rhinitis. 
Several studies showing that omalizumab had beneficial 
effects in patients with latex allergies56,57 or peanut allergy58 
have been reviewed previously.9 Recent case studies have 
also revealed encouraging outcomes in omalizumab-treated 
patients with allergic bronchopulmonary aspergillosis.59–64 
It has also been suggested that omalizumab may have 
potential benefits in patients with eosinophil-associated 
gastrointestinal disorders (EGIDs), which are often associ-
ated with atopy;65 in 9 patients with EGIDs, treatment with 
omalizumab resulted in significant reductions in eosinophil 
counts and basophil and dendritic cell FcεRI expression, 
as well as significant improvements in symptom scores.65 
Several small studies and case reports have been published 
which indicate a potential benefit of omalizumab therapy in 
patients with urticaria. In one small proof of concept study 
in patients with chronic autoimmune urticaria (n = 12), 
12 to 16 weeks following initiation of omalizumab, mean 
Urticaria Activity Score (p = 0.0002) and rescue medication 
(p = 0.004) use were significantly decreased, and quality of 
life was improved (p  0.05).66
Anti-inflammatory activity
In addition to the effects of omalizumab on inflammatory 
mediator release from mast cells and basophils, and the down-
regulation of FcεRI expression described earlier, the effects 
of omalizumab on several other markers of inflammation 
have been evaluated, with particular reference to effects on 
eosinophils in light of their prominent role in inflammatory 
responses.5,24 In two studies, measurements of circulating 
blood eosinophils were made in patients with moderate-
to-severe persistent asthma.15,19 A pooled analysis found 
that omalizumab reduced mean peripheral blood eosino-
phil counts (LSM change from baseline –0.119 × 109/L; 
p  0.0001), while there was no significant change in the 
placebo group.67
Omalizumab has also been shown to reduce sputum 
and bronchial eosinophilia in a study of 45 patients with 
mild-to-moderate persistent asthma and persistent airway 
inflammation.23 At 16 weeks, reductions in mean percent-
age sputum eosinophil counts were significantly greater in 
omalizumab-treated patients (from 4.8% at baseline to 0.6% 
at Week 16) than in placebo recipients (from 5.8% to 2.3%; 
between treatment group difference: p = 0.005). Eosinophil 
counts in the bronchial submucosa also decreased from 
8.0 cells/mm2 at baseline to 1.5 cells/mm2 at Week 16 in the 
omalizumab group (p  0.001), but were almost unchanged 
in the placebo group. Omalizumab was associated with 
significantly greater reductions in FcεRI+ (p  0.01), CD3+ 
(p  0.05) and IL-4+ (p  0.05) cells in the epithelium and 
submucosa and in CD4+ (p  0.01) and CD8+ (p  0.05) cells 
in the submucosa. Observed reductions in CD3+ (p = 0.001), 
CD4+ (p = 0.005), CD8+ (p = 0.005) T-lymphocytes and 
CD20+ (p = 0.02) B-lymphocytes were also significantly 
greater in omalizumab recipients than in the placebo group. 
These findings have been confirmed in a study in 25 patients 
with mild allergic asthma.27 The median sputum percent-
age eosinophil count was reduced from 4.0% at baseline to 
0.5% at 12 weeks in omalizumab-treated patients, compared 
with an increase from 2.2% to 2.6% in the placebo group 
(between treatment group difference: p = 0.003). There was 
also a significant reduction in median activated eosinophil 
counts in biopsies in the omalizumab group (from 15.0 to 
2.0 cells/0.1 mm2), with little change in the placebo group 
(from 14.5 to 11.0 cells/0.1 mm2; between treatment group 
difference: p  0.005). Additionally, omalizumab-treated 
patients had significant (p  0.0001) reductions in submu-
cosal IgE+ cells compared with placebo and a significant 
(p = 0.021) reduction in CD4+ T-lymphocytes compared with 
baseline. Taken together, these findings indicate that reduc-
tions in asthma exacerbations brought about by omalizumab 
may be mediated through attenuation of airway eosinophilia, 
while the reductions in IL-4+ cells may be important in light of 
the documented association between persistent IL-4 produc-
tion and severe or corticosteroid-resistant asthma.23,68
Several studies have provided information on other 
anti-inflammatory effects of omalizumab. Reductions in 
IL-13+ lymphocytes and decreases in circulating eosinophil 
counts and IL-13, IL-5 and IL-8 levels were seen in a study 
of 35 patients with moderate-to-severe allergic asthma 
treated with omalizumab.69 Th2 cytokines such as IL-4, 
IL-5 and IL-13 are believed to promote the recruitment 
and activation of mast cells and eosinophils.68 In another 
study in 19 patients with moderate-to-severe asthma and 
a history of allergic rhinitis, 12 weeks of treatment with 
omalizumab resulted in significantly greater eosinophil 
apoptosis (60.1% Annexin-positive cells), compared with 
placebo (45.6%; p = 0.004).70 No significant change in the 
marker 7-amino-actinomycin was seen, indicating eosinophil 
apoptosis rather than necrosis. This study also revealed a 
reduction in peripheral T-lymphocytes positive for granulo-
cyte macrophage colony stimulating factor (GMCSF) (mean 
10.5%), compared with placebo (12.1%; p = 0.018) and 
baseline (17.7%; p = 0.0039), and significant reductions in Journal of Asthma and Allergy 2009:2 56
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the IL-2+ and IL-13+ T-lymphocytes in omalizumab treated 
patients, compared with placebo (both p = 0.027). Omali-
zumab was also shown to reduce histamine release from 
basophils in a study of 17 patients with allergic asthma.71 
Reduction in maximal histamine release (p  0.01) and 
cellular allergen sensitivity (p  0.05) from baseline were 
significantly greater in the omalizumab group after 16 weeks 
of therapy compared with the placebo group, and there were 
corresponding changes in airway resistance, β2-agonist use, 
skin prick tests, wheal area and the investigator’s overall 
assessment of treatment effectiveness.
Anti-inflammatory effects have also been noted in studies 
of omalizumab in combination with SIT in patients with 
allergic rhinitis. For example, omalizumab plus SIT normal-
ized myeloid dendritic cell numbers during the grass pollen 
season in children with SAR72 and resulted in stable eosino-
phil cationic protein (ECP) levels and significant (p  0.05) 
reductions in tryptase in a study of 225 children with a history 
of seasonal allergic rhinoconjunctivitis.73
Overall, there is compelling evidence that omalizumab 
has powerful anti-inflammatory effects in patients with 
allergic asthma and/or allergic rhinitis. Omalizumab has been 
shown to bring about substantial reductions in the activity of 
IgE, eosinophils, basophils, mast cells, and dendritic cells, 
resulting in attenuation of the acute and chronic effector 
phases of allergic inflammation.74
Safety of omalizumab
Safety in adults and adolescents
The safety of omalizumab has been evaluated in a pooled 
analysis of 7500 adult or adolescent (12 years of age) 
patients with asthma, rhinitis or related conditions who 
received omalizumab in clinical trials.75 Overall, omalizumab 
had a good safety and tolerability profile and there was no 
evidence of an increased risk of malignant neoplasia or 
thrombocytopenia.
While omalizumab EU prescribing information includes 
a numerical imbalance in malignancies in the omalizumab 
group compared with the control group in pooled trials 
(0.5% and 0.18% respectively), the diversity in cancer 
type, short duration of exposure to omalizumab, and clini-
cal features of individual cases makes a causal relationship 
unlikely29. Furthermore, a comparison of cancer rates from 
omalizumab clinical trials with the National Institutes of 
Health (NIH) Surveillance, Epidemiology and End Results 
(SEER) database found that the overall number of can-
cers reported in the omalizumab group was similar to that 
expected in the general population, while the number in the 
control group was one-third of that expected.76 To December 
2007, approximately 106,000 person-years of exposure 
to omalizumab have been achieved in the post-marketing 
setting, and only a small number of malignancies reported 
(120 cases, or 0.11 per 100 person years; author correspon-
dence with Novartis, data on file).
In preclinical studies, a decrease in platelet counts was 
observed in cynomolgus monkeys at doses approximately 
4 to 20 times higher than anticipated maximum clinical 
serum concentrations, and in clinical trials, a few patients had 
platelet counts below the lower limit of the normal laboratory 
range; however, none were associated with bleeding episodes 
or a decrease in hemoglobin. No pattern of persistent platelet 
decrease has been reported in humans, although isolated 
cases of idiopathic thrombocytopenia have been reported in 
the post-marketing setting.29
In clinical trials, omalizumab was associated with a low 
incidence of anaphylaxis (0.14% in omalizumab-treated 
patients and 0.07% in control patients). Post-marketing 
surveillance in approximately 57,300 patients treated dur-
ing 2003 to 2006 has found that anaphylaxis after use of 
omalizumab occurred in approximately 0.2% of patients.77 
A review of clinical trial and post-marketing surveillance data 
between June 2003 and December 2005 was also conducted 
by Omalizumab Joint Task Force (OJTF) of the American 
Academy of Allergy, Asthma and Immunology and the 
American College of Allergy, Asthma and Immunology 
Executive Committees.78 This review found that 35 patients 
had 41 episodes of omalizumab-associated anaphylaxis 
out of a total of 39,510 treated patients, corresponding to a 
reporting-rate of 0.09%. Based on this observation, the OJTF 
has recommended keeping patients under observation for 2 
hours after the first three omalizumab injections and for 30 
minutes after all injections;78 however, this advice is not man-
datory and can be modified, based on the physician’s clinical 
judgment after discussion of the risks with the patient.
In the total population of patients enrolled in controlled 
clinical trials, the incidence of AEs was similar between 
the omalizumab-treated patients and the control group, and 
most events were of mild to moderate severity.75 The most 
frequently reported AEs were nasopharyngitis, upper respira-
tory tract infection and sinusitis; these and other individual 
AEs occurred with similar frequencies in the omalizumab 
and control groups.
Safety in children
The good safety profile of omalizumab observed in adults 
and adolescents is also observed in children. In a study of Journal of Asthma and Allergy 2009:2 57
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children with asthma, omalizumab was generally safe and 
well tolerated.44 No serious treatment-related AEs were 
reported during the study and the overall frequency and dis-
tribution of AEs were similar in the omalizumab and placebo 
groups. Most AEs were of mild to moderate severity. This 
promising safety profile was maintained over 52 weeks fol-
lowing a 24-week extension to the study by Milgrom et al79 
with no new or more serious AEs reported. In the more recent 
52-week evaluation of efficacy and safety of omalizumab in 
children, omalizumab showed no difference in the overall 
incidence of AEs compared with placebo over the duration 
of the study.46 The most common AEs reported were naso-
pharyngitis, sinusitis and upper respiratory tract infection, 
and AEs were mostly (91%) of mild or moderate severity. 
No anaphylaxis to omalizumab occurred, and there were no 
cases of malignancies or thrombocytopenia in omalizumab-
treated children.
Cost-effectiveness
The annual cost of treatment with omalizumab is higher than 
conventional asthma therapies; in their assessment of the use 
of omalizumab in Scotland, the Scottish Medicines consor-
tium estimated the annual cost of omalizumab therapy to be 
£3,330–19,980 (approximately  4,900 to  29,500) in June 
2007.80 Therefore, consideration should be given to the cost-
effectiveness of this therapy in patients with severe persistent 
allergic asthma. Several studies with varying methodologies 
have evaluated the cost-effectiveness of omalizumab.
In 3 analyses in patients with inadequately controlled, 
severe persistent asthma despite high-dose ICS plus a 
LABA,81–83 a Markov cohort model was used to estimate the 
cost-effectiveness of adding omalizumab to standard asthma 
therapy and compared the cost of lifelong standard therapy 
with that of 5 years of omalizumab followed by lifelong stan-
dard therapy. Incremental cost effectiveness ratios (ICERs) 
were calculated as the difference in total costs between 
omalizumab and standard treatment per quality-adjusted life 
year (QALY). Importantly, these analyses accounted for the 
fact that omalizumab should be discontinued after 16 weeks 
in patients who do not respond to therapy. These studies 
found that add-on therapy with omalizumab resulted in ICER 
values of  56,091 (INNOVATE efficacy data applied to 
Sweden as the reference country),83  31,209 (ETOPA data 
applied to Canada),81  44,910 (INNOVATE data applied to 
the Netherlands)82 and  26,694 (ETOPA data applied to the 
Netherlands).82 In a review of these studies, Sullivan and Turk 
concluded that these ICER values indicated that omalizumab 
is cost effective at a willingness-to-pay value of  60,000.84
An analysis by Oba and Salzman, conducted from 
the perspective of third-party payers used assessed cost-
effectiveness in terms of the daily cost to achieve defined 
outcomes.85 The daily cost to achieve each additional day 
in which asthma was controlled was $523, while the daily 
cost of a 0.5-point increase in Asthma Quality of Life 
Questionnaire score was $378 (US$ values from 2003).85 In 
their review, Sullivan and Turk noted that these measures 
of cost-effectiveness were more difficult to interpret than 
incremental costs per QALY as a guide to resourcing deci-
sions.84 They also noted that this analysis used data from a 
less severe patient population and did not take account of the 
patients’ responses to omalizumab at 16 weeks.84
In another study, Wu et al showed that omalizumab 
provided an additional 1.7 quality-adjusted months at an 
incremental cost of US$131,000 over 10 years (correspond-
ing to a cost-effectiveness ratio of US$821,000 per QALY 
gained), and concluded that omalizumab is not cost-effective 
for most patients with severe asthma.86 However, as Sullivan 
and Turk note, the model of Wu et al was based on a popu-
lation with severe asthma, but used data from patients with 
mild-to-severe asthma and remains to be validated in patients 
with more severe disease.84 Additionally, one of the main 
components of this analysis was health-related quality of life, 
which is based on prediction of FEV1. Omalizumab has little 
impact on FEV1, which is not strongly related to QALYs, and 
the model may therefore not adequately capture the benefits 
of omalizumab.84 Overall, data from patients with severe 
asthma indicate that the cost-effectiveness of omalizumab in 
treatment responders compares favorably with that of other 
biologic treatments for chronic disease.84
Experience in clinical practice
To April 2007, an estimated 68,000 patients with moderate-
to-severe persistent allergic asthma have been treated with 
omalizumab in clinical trials and real-life practice. Several 
studies that have evaluated the use of omalizumab in clinical 
practice have revealed outcomes consistent with the results 
of the clinical trials programme. For example, one study 
in 147 patients treated in French practices showed that in 
patients with follow-up data of at least 5 months, there were 
62% fewer exacerbations requiring OCS, 65% fewer emer-
gency department visits and 29% fewer hospitalizations per 
year than in the year prior to omalizumab treatment.87 The 
observed safety and tolerability of omalizumab was similar 
to that seen in clinical trials.
Real-life data have also revealed the steroid-sparing 
potential of omalizumab. Pooled data from surveys of UK Journal of Asthma and Allergy 2009:2 58
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and French clinicians was evaluated to examine the effects 
of omalizumab on maintenance OCS requirements in patients 
treated with omalizumab for at least 16 weeks for severe 
persistent allergic asthma.88 Among the 173 patients included 
in the analysis, 97 were receiving maintenance OCS at base-
line. Of these patients, 61.9% stopped or reduced their OCS 
treatment, with 18.6% stopping altogether. These findings 
have been confirmed in a larger pooled analysis of data from 
clinicians in France, the UK and Germany. In this analysis 
of patients who received omalizumab for at least 16 weeks 
(n = 411), 199 patients were receiving maintenance OCS at 
baseline. Of these, 55.3% stopped or reduced OCS dose and 
21.1% stopped altogether.89
German real-life data in patients with severe persistent 
allergic (IgE-mediated) asthma (n = 280) has also shown 
reductions in exacerbations (82%), hospitalizations (78%), 
unscheduled healthcare contacts (81%), and daily (76%) and 
nocturnal symptoms (84%) after 6 months of omalizumab, 
compared with the (period-adjusted) year before treatment. 
Quality of life was also improved (increase in Mini-Asthma 
Quality of Life Questionnaire overall score from 2.9 to 4.5), 
and efficacy and tolerability were rated as excellent or good 
by the majority of physicians (82% and 95%) and patients 
(86% and 94%).90
Taken together, these data demonstrate that benefits 
observed in clinical trials translate well into real-life clinical 
practice, with clinically relevant decrease in asthma-related 
events, reduction or cessation of maintenance OCS use, 
reduction of daytime and night-time symptoms, and improve-
ments in quality of life.
Future prospects for development 
of omalizumab
Liquid formulation
Omalizumab is currently formulated as a sterile, preservative-
free, lyophilized powder and solvent. Once mixed, it can 
take in excess of 20 minutes for the powder to dissolve 
completely.29 The development of a liquid formulation, which 
offers advantages in terms of convenience to the prescriber, 
is ongoing. The pharmacokinetics and pharmacodynamics of 
this liquid formulation of omalizumab have been compared 
with the current lyophilized formulation in an open-label, 
parallel-group study of 155 atopic but otherwise healthy 
adults.91 Total omalizumab, free and total IgE, and safety 
were determined for 84 days post-administration, and blood 
samples were collected. As the 90% confidence intervals of 
the dose-adjusted AUC0−inf and Cmax mean ratios were between 
pre-specified values, pharmacokinetic (PK) bioequivalence 
was demonstrated. Pharmacodynamic (PD) parameters also 
showed that free IgE and total IgE were comparable between 
the lyophilized and liquid formulations. The two formulations 
were found to be bioequivalent, resulting in similar exposure 
to omalizumab. No serious AEs were reported during the 
study, and AEs were comparable between formulations.
Dosing table expansion
Treatment of patients with omalizumab is currently limited 
to patients with a baseline total serum IgE of 700 IU/mL 
and body weight 150 kg according to the omalizumab 
dosing table. A recent study used clinical trial data15,16,31,35 
alongside unpublished bioequivalence study data on omali-
zumab, free IgE and total IgE concentrations in a predictive 
check of omalizumab-IgE binding model. Model-predicted 
IgE levels correlated well with clinical outcomes from 
the same clinical trials to demonstrate their relationship, 
allowing exploration of doses and regimens for patients 
with free IgE or bodyweight values outside the current EU 
dosing table.92 Ultimately, this approach may enable future 
treatment of patients who cannot receive omalizumab at 
present.
Disease modification
Analysis of data from the 28 week INNOVATE has shown 
that upon withdrawal of omalizumab, IgE levels return to 
baseline and symptoms re-emerge,93 and the current rec-
ommendation is that omalizumab should be administered 
according to the dosing table in those patients who respond 
to therapy for as long as they continue to benefit. However, 
one small study in which patients received long-term omali-
zumab therapy suggests that prolonged treatment may have 
the potential to alter the course of asthma. Patients with 
allergic asthma (n = 18) received omalizumab for approxi-
mately 6 years before discontinuation of therapy.94 Between 
6 and 14 months after discontinuation, 13 of 18 patients’ 
symptoms remained the same as, or had improved from, 
their symptoms during treatment. The majority were in a 
stable clinical condition and reported high quality of life, 
no increased nightly asthma attacks, no emergency visits 
and little or no increase in medication. Sensitivity to cat 
allergen peaked 4 months after discontinuation and subse-
quently decreased to levels less than in control patients, and 
non-reactive basophils were seen in 6 out of 14 patients at 
12 months. Overall, these findings indicate that most patients 
had mild asthma 12 to 14 months after the end of prolonged 
treatment with omalizumab, with persistent down-regulation Journal of Asthma and Allergy 2009:2 59
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of basophil reactivity (and presumably mast cell reactivity) 
suggesting that treatment was exerting a long-term disease-
modifying effect.
There is also emerging evidence that long-term treatment 
with omalizumab reduces IgE production towards normal 
(non-atopic) rates. A study used two versions of a PKPD 
model, one of which allowed variation in IgE produc-
tion over time, while the other had a fixed IgE production 
rate. The estimated mean initial IgE production rate was 
1840 µg/day. In control patients, IgE production appeared to 
increase slowly at an average rate of 3.6% per year, while in 
omalizumab-treated patients IgE production rate decreased 
and was projected to stabilize at 132 µg/day.95
Further insight into the potential disease modifying 
effects of omalizumab will be provided by the ongoing 
EXPLORE study, a randomized, multicenter, double-blind, 
placebo-controlled, parallel-group trial, which is examining 
the effects of 78 weeks of add-on omalizumab treatment on 
markers of airway inflammation and remodelling (number of 
subepithelial eosinophils, mast cells, CD4+ T-lymphocytes 
and reticular basement membrane thickness) in patients with 
moderate-to-severe persistent allergic asthma receiving ICS 
and a LABA.
Conclusions
IgE is central to the pathophysiology of allergic asthma 
and related conditions such as allergic rhinitis, providing 
a strong rationale for the development of anti-IgE therapy 
for the treatment of these diseases. By binding to free IgE, 
omalizumab reduces the level of circulating free IgE by up to 
99%, prevents IgE from attaching to mast cells and basophils, 
down-regulates FcεRI expression, and attenuates the inflam-
matory response to allergens. There is accumulating evidence 
to show that omalizumab reduces the activity of a variety of 
pro-inflammatory cells (including eosinophils, mast cells and 
basophils) and down-regulates release of pro-inflammatory 
mediators, thereby attenuating both the acute and chronic 
effector phases of allergic inflammation. In addition, the 
effects of omalizumab on antigen-presenting cells (dendritic 
cells) indicate that it may also block the sensitization phase, 
as well as the effector phase.
The benefits of this novel anti-inflammatory mechanism 
of action have been well documented in an extensive pro-
gramme of clinical trials, including the INNOVATE study, 
which have shown that omalizumab reduces asthma exacer-
bations, severe asthma exacerbations, inhaled corticosteroid 
requirements, and emergency visits, as well as significantly 
improving asthma-related quality of life, morning PEF and 
asthma symptom scores in patients with severe allergic 
(IgE-mediated) asthma. Results from clinical trials have also 
been replicated in routine clinical practice, where consider-
able reduction in the need for maintenance OCS following 
omalizumab has been reported.
As it is difficult to predict which patients will respond to 
omalizumab, it is recommended in the EU that the physician’s 
overall assessment should be used to identify responders after 
16 weeks of therapy. This way, it is possible to target the 
treatment to the patients most likely to benefit. When treat-
ment is directed at these responders, omalizumab has been 
shown to provide cost effective therapy for inadequately con-
trolled severe persistent allergic (IgE-mediated) asthma.
Ongoing studies continue to evaluate the treatment 
benefits of omalizumab and guide therapy. Additionally 
indications are that omalizumab could benefit children 
with inadequately controlled moderate-to-severe persistent 
asthma, and clinical trials in this population show results 
which are consistent with those in the adult population. The 
potential for disease-modification in asthma is also currently 
being investigated, as is the use of omalizumab in other 
IgE-mediated conditions.
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